Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Telmisartan 40mg Clear all

Conditions: Covid19
Interventions: Telmisartan Oral Product, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Alzheimer's Disease
Interventions: Telmisartan 20mg, Telmisartan 40mg, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Stroke
Interventions: Telmisartan, Metformin, Cilostazol; Drug
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Hypertension
Interventions: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more

Conditions: Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions: Telmisartan Pill; Drug
Lead sponsor: Xiaoduo Fan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Heart Failure, Systolic, Frailty
Interventions: sacubitril/valsartan, Angiotensin II Receptor Blockers; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Hypertension
Interventions: Telmisartan 80, Amlodipine 10; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 15
States / cities: Long Beach, California • Tustin, California • Fort Lauderdale, Florida + 12 more

Conditions: Hypertension
Interventions: Telmisartan, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 19 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more

Conditions: Hypertension, Vascular Stiffness, Aging
Interventions: Blood pressure treatment algorithm; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin

Conditions: Hypertension
Interventions: Telmisartan, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 70
States / cities: Glendale, Arizona • Tempe, Arizona • Tucson, Arizona + 58 more

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Hypertension
Interventions: telmisartan, valsartan; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 16
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 12 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Telmisartan, Placebo, Clozapine, Olanzapine; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Ovarian Cancer
Interventions: Telmisartan; Drug
Lead sponsor: Tyler J Curiel; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Manchester, New Hampshire

Conditions: HIV-1 Infection
Interventions: Telmisartan; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 8 more

Conditions: Abdominal Aortic Aneurysm
Interventions: Telmisartan, Placebo; Drug
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 50 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Endothelial Dysfunction
Interventions: Telmisartan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Insulin Resistance
Interventions: MICARDIS® (telmisartan); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Westlake Village, California + 5 more

Conditions: Hypertension, Insulin Resistance, Dyslipidemia
Interventions: Telmisartan; Drug
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: Telmisartan, Standard of Care Regimen; Drug · Other
Lead sponsor: Tyler J Curiel; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: High Blood Pressure
Interventions: Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 59 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 101
States / cities: Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more

Search by objective public record fields.

INvestigating TELmisartin Study

Health Evaluation in African Americans Using RAS Therapy

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Arterial Stiffness and Blood Pressure

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

HALT Progression of Polycystic Kidney Disease Study A

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

Telmisartan in Prostate Cancer

Treating Nocturnal Hypertension and Nocturia in African American Men

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension